Karen Anderson

Karen Anderson, Director of healthcare equity research at Morningstar Research Services, dives into the robust performance of healthcare stocks during market volatility. She discusses the significant influence of GLP-1 drugs like Ozempic and their future in biopharma. The conversation highlights how regulatory changes and demographic shifts, particularly an aging population, shape investment opportunities. Anderson also contrasts valuation approaches within the healthcare sector and shares her insights on potential picks for savvy investors.